Skip Navigation
Menu
ACP Journal Club |17 January 2017

Review: In type 2 diabetes, sodium–glucose cotransporter 2 inhibitors do not increase major CV events or mortality

James Brophy, MD, FRCP, FACC, PhD

Article, Author, and Disclosure Information
FULL TEXT
Tang H, Fang Z, Wang T, et al. Meta-analysis of effects of sodium-glucose cotransporter 2 inhibitors on cardiovascular outcomes and all-cause mortality among patients with type 2 diabetes mellitus. Am J Cardiol. 2016;118:1774-80. 27666177

GIM/FP/GP:

Image: rating_6.jpg

Endocrinology:

Image: rating_6.jpg

In type 2 diabetes mellitus, what are the effects of sodium–glucose cotransporter 2 (SGLT2) inhibitors for major adverse cardiovascular events (MACE) and all-cause mortality?
Included studies compared SGLT2 inhibitors (canagliflozin, dapagliflozin, empagliflozin), alone or combined with other antidiabetes drugs, with placebo, each other, or other active antidiabetes drugs in adults ≥ 18 years of age with type 2 diabetes; had duration ≥ 24 weeks; and reported ≥ 1 outcome of interest. Primary outcomes were all-cause mortality and MACE (cardiovascular [CV] death, nonfatal myocardial infarction, or nonfatal stroke). Secondary outcomes included heart failure (HF) or hospitalization for HF, unstable angina or hospitalization for unstable angina, atrial fibrillation, and transient ischemic attack. PROSPERO registration CRD42015026853.
FULL TEXT
PDF
Not Available
Citations
Citation

Brophy J. Review: In type 2 diabetes, sodium–glucose cotransporter 2 inhibitors do not increase major CV events or mortality. Ann Intern Med. 2017;166:JC7. doi: 10.7326/ACPJC-2017-166-2-007

Download citation file:

© 2018

×
Permissions

Published: Ann Intern Med. 2017;166(2):JC7.

DOI: 10.7326/ACPJC-2017-166-2-007

©
2017 American College of Physicians
0 Citations

Related Articles
Review: Sulfonylureas are associated with overall mortality and CV events vs other antihyperglycemics in T2DM
Annals of Internal Medicine; 166 (8): JC40
In patients with SBP ≥ 130 mm Hg and CV risk, intensive vs standard BP control reduced CV events and mortality
Annals of Internal Medicine; 164 (4): JC15
Update in Endocrinology: Evidence Published in 2010
Annals of Internal Medicine; 154 (10): 684-689
Mortality Trends in Men and Women with Diabetes, 1971 to 2000
Annals of Internal Medicine; 147 (3): 149-155
View MoreView Less

Journal Club
Review: Sulfonylureas are associated with overall mortality and CV events vs other antihyperglycemics in T2DM
Annals of Internal Medicine; 166 (8): JC40
In patients with SBP ≥ 130 mm Hg and CV risk, intensive vs standard BP control reduced CV events and mortality
Annals of Internal Medicine; 164 (4): JC15
Review: Adjunctive corticosteroids reduce mortality and clinical failure in adult inpatients with CAP
Annals of Internal Medicine; 168 (8): JC40
Review: Adjunctive corticosteroids do not reduce mortality or clinical failure in adult inpatients with CAP
Annals of Internal Medicine; 168 (8): JC41
View MoreView Less

Related Point of Care
Type 2 Diabetes
Annals of Internal Medicine; 162 (5): ITC1
Type 2 Diabetes
Annals of Internal Medicine; 152 (5): ITC3-1
Type 2 Diabetes
Annals of Internal Medicine; 146 (1): ITC1-1
Diabetic Ketoacidosis
Annals of Internal Medicine; 152 (1): ITC1-1
View MoreView Less

Related Topics
Cardiology
Coronary Risk Factors
Diabetes
Endocrine and Metabolism

Cardiology, Coronary Risk Factors, Diabetes, Endocrine and Metabolism.

PubMed Articles
Reduced plasma fibrin clot permeability is associated with recurrent thromboembolic events in patients with antiphospholipid syndrome.
Rheumatology (Oxford) 2018.
A new modeling and inference approach for the Systolic Blood Pressure Intervention Trial outcomes.
Clin Trials 2018.
View More

Results provided by: PubMed

CONTINUE WITH LIMITED ACCESS
Annals of Internal Medicine
To receive access to the full text of freely available articles, alerts, and more. You will be directed to acponline.org to complete your registration.
×
acp link acp
silverchair link silverchair

Copyright © 2018 American College of Physicians. All Rights Reserved.

Print ISSN: 0003-4819 | Online ISSN: 1539-3704

Privacy Policy

|

Conditions of Use

×

You need a subscription to this content to use this feature.

×
PDF Downloads Require Access to the Full Article.
Annals of Internal Medicine
To receive access to the full text of freely available articles, alerts, and more. You will be directed to acponline.org to complete your registration.
×
Access to this Free Content Requires Users to be Registered and Logged In. Please Choose One of the Following Options
Annals of Internal Medicine
To receive access to the full text of freely available articles, alerts, and more. You will be directed to acponline.org to complete your registration.
×